Tom Wilbur

Husband, Dad, Public Affairs @PhRMA | Fmr Cap Hill | CMU & MSU alum | No grind no shine

[Tom Wilbur @TSWilbur]

Patients speak out: #MFN won't address my affordability concerns https://t.co/Rlq98NdEq2

[Tom Wilbur @TSWilbur]

As a history buff, I found this absolutely fascinating and well done. Nearly 200 primary sources!

[Adam J. Fein @DrugChannels]

𝐓𝐡𝐞 𝐌𝐨𝐬𝐭 𝐈𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 340𝐁 𝐩𝐚𝐩𝐞𝐫 𝐘𝐨𝐮'𝐥𝐥 𝐄𝐯𝐞𝐫 𝐑𝐞𝐚𝐝

If you care about #340B policy, use the long weekend to read this outstanding new paper:

"Stretching Scarce Authorizing Legislation as Far as Possible: A Legislative History of the 340B Drug Pricing Program."

Sayeh Nikpay @saynikpay and her colleagues went back to the early 1990's to reconstruct the program's origins. Their research draws on interviews with 18 key participants and 175 primary source documents spanning 1990–1992.

Their conclusion is difficult to ignore:

340B was originally designed as a narrow policy solution to address an unintended consequence of Medicaid’s best-price provision and to support core safety-net providers.

But the paper makes a compelling case that today’s program extends far beyond Congress’s original intent.

Whether you support or oppose the current structure of 340B, this paper is essential reading for anyone who wants to understand how we got here.

Read it here: https://t.co/MrD8O31wNI

One especially fascinating detail: The disproportionate share hospital (DSH) eligibility threshold of 11.75% was chosen to qualify two specific hospitals and secure bipartisan support from Senator Hatch and Representative Bliley.

In other words, the threshold was not grounded in any broader scientific or policy rationale.

Amazing.

[Tom Wilbur @TSWilbur]

New analysis highlights access to new medicines in the United States and abroad https://t.co/6K1oRCx47n

[Tom Wilbur @TSWilbur]

MFN won’t lower costs when insurers call the shots https://t.co/sWDKrTZf4A

[Nyah Phengsitthy @nyahphengsitthy]

Scoop: PhRMA, one of the most powerful lobbying groups in Washington, is launching a new seven-figure advertising blitz targeting a federal drug discount program that has ballooned in recent years. https://t.co/CvcGwREgEZ

[PhRMA @PhRMA]

On the Hill this week, we heard how insurers are standing between patients and care.

New data shows 70% of patients are initially denied coverage for a prescribed medicine, delaying or preventing treatment.

Patients should not face red tape. It is time to put them first.

https://t.co/i09uR0eYby

[Tom Wilbur @TSWilbur]

WaPo ed board says #340B has become “corporate welfare” https://t.co/JIQsdUaXWQ

[Tom Wilbur @TSWilbur]

Survey confirms too many insured Americans face barriers to reliable health care https://t.co/HfWAzDSLJK

[Tom Wilbur @TSWilbur]

@casualclubguy Belvedere logo is so elite

[Tom Wilbur @TSWilbur]

Voters voice concerns on government price controls: https://t.co/Ve0aXVyvy4

[PhRMA @PhRMA]

NEW: IQVIA released a new study exposing a patient medicine denial crisis.

🚨 7️⃣0️⃣% of patients seeking branded medicines through commercial insurance were initially denied coverage, forcing patients to give up on their medicines or navigate a maze of appeals. Delays like that can have serious consequences for health outcomes.

Learn more about the denial crisis ➡️ https://t.co/bvnatZFJip

[PhRMA @PhRMA]

After more than a decade, PhRMA President and CEO Steve Ubl will step down at the end of the year. 

Read more: https://t.co/BE7ENvMcvE

[Michigan State Men's Basketball @MSU_Basketball]

28 STRAIGHT.

[Tom Wilbur @TSWilbur]

No hassle, hidden markups or fees: https://t.co/EUgu8Du9kr

[Tom Wilbur @TSWilbur]

Fantastic event focused on working to shape the future of American health care & improve patient outcomes.

[PhRMA @PhRMA]

PhRMA Forum 2026 reinforced why American leadership matters: innovation, leadership and a commitment to protecting the ecosystem that delivers breakthroughs for patients.

Thank you to our guests and speakers for engaging in a robust conversation around sustaining our position of leadership.

https://t.co/yE3GeXfJxt

[Tom Wilbur @TSWilbur]

Myth: Recent reforms solve the #PBM problem

Fact: Recently passed leg. is an important step forward to reign in PBMs but problems remain as they continue to evolve their business model, leaving patients behind.

https://t.co/y0p9asXuRY

[PhRMA @PhRMA]

PhRMA COO @lreilly71 is testifying today before the @HouseCommerce Health Subcommittee as lawmakers work on bipartisan solutions to lower health care costs and examine the prescription drug supply chain.

Watch the hearing today, starting at 10:15am: https://t.co/uznqJ5SiTg

[Scott LaGanga @ScottLaGanga]

States have led the way on PBM reform, great to see this coming out of DC.

[Voters for Cures @votersforcures]

🚨 PBM REFORM HAS BEEN SIGNED INTO LAW

This law represents a major win for patient access, and it is a direct result of the years of hard work from our advocates that have ensured PBMs and insurers are held accountable.

[Tom Wilbur @TSWilbur]

“We applaud the broad, bipartisan coalition of lawmakers who came together to pass meaningful #PBM reform. These reforms are a win for patients, pharmacists, providers & employers who have urged Washington to hold PBMs accountable." - @steveubl

https://t.co/IgxP8vqe13